New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2013
11:18 EDTIMOS, NIHD, CTIC, NTE, EXELHigh option volume stocks: NIHD EXEL CTIC IMOS NTE
News For NIHD;EXEL;CTIC;IMOS;NTE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2015
06:11 EDTIMOSChipMOS reports March revenue up 2% to $56.8M vs. $55.7M last year
Subscribe for More Information
April 9, 2015
08:32 EDTEXELExelixis' cabozantinib granted FDA fast track designation
Exelixis announced that the U.S. Food & Drug Administration has granted Fast Track designation to cabozantinib for treatment of patients with advanced renal cell carcinoma who have received one prior therapy. Cabozantinib is the company’s lead compound and inhibits the activity of multiple tyrosine kinases including MET, VEGFRs and RET. The FDA created the Fast Track process to facilitate the development and expedite the review of drugs to treat serious diseases and address unmet medical needs. Fast Track designation confers important benefits, including the potential eligibility for Priority Review of a New Drug Application, if relevant criteria are met.1 Cabozantinib is the subject of METEOR, an ongoing phase 3 pivotal trial in patients with metastatic RCC who have experienced disease progression following treatment with at least one VEGFR tyrosine kinase inhibitor. Patients are randomized 1:1 to receive 60 mg of cabozantinib daily or 10 mg of everolimus daily. The primary endpoint of METEOR is progression-free survival, and secondary endpoints include overall survival and objective response rate. Exelixis expects to release top-line results from the trial in the second quarter of 2015. In addition to the metastatic RCC development program, Exelixis is also evaluating cabozantinib in CELESTIAL, a phase 3 pivotal trial in second-line hepatocellular carcinoma.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use